Table 1 Baseline patient characteristics and biopsy outcomes for all patients with PIRADS 3-5 lesions by race.
Asian | Black | White | Overall | p-value | |
|---|---|---|---|---|---|
(n = 36) | (n = 88) | (n = 414) | (n = 665) | ||
Age, median (IQR) | 67 (61–70) | 62 (58.5-68)d | 66.5 (61-71.5) | 66 (61–71) | 0.001 |
Biopsy approach, n (%) | 0.6 | ||||
Transrectal | 19 (53) | 44 (50) | 192 (46) | 320 (48) | |
Transperineal | 17 (47) | 44 (50) | 222 (54) | 345 (52) | |
Family History of Prostate Cancer | |||||
Yes, n(%) | 3 (8) | 11 (13) | 92 (22) | 115 (17) | 0.004 |
PSAa, median (IQR) | 5.88 (4.53-8.38) | 6.50 (5.00-9.75)d | 5.53 (4.33-7.47) | 5.79 (4.48-8.00) | 0.02 |
PSADb, median (IQR) | 0.13 (0.09-0.24) | 0.17 (0.11-0.31)d | 0.13 (0.09-0.20) | 0.14 (0.09-0.21) | 0.01 |
PI-RADSc, n (%) | 0.3 | ||||
3 | 7 (19) | 20 (23) | 100 (24) | 153 (23) | |
4 | 16 (44) | 50 (57) | 196 (47) | 319 (48) | |
5 | 13 (36) | 18 (20) | 118 (29) | 193 (29) | |
Highest Grade Group, n (%) | 0.11 | ||||
Benign | 14 (39) | 14 (16) | 117 (28) | 177 (27) | |
GG1 | 3 (8) | 15 (17) | 74 (18) | 102 (15) | |
GG2 | 8 (22) | 30 (34) | 121 (29) | 208 (31) | |
GG3 | 5 (14) | 14 (16) | 47 (11) | 81 (12) | |
GG4 | 2 (6) | 5 (6) | 20 (5) | 34 (5) | |
GG5 | 4 (11) | 10 (11) | 35 (9) | 63 (9) | |
